Efficacy and safety of olanzapine suppositories in terminally ill patients with delirium or nausea and vomiting.

Efficacy and safety of olanzapine suppositories in terminally ill patients with delirium or nausea and vomiting. - Efficacy and safety of olanzapine suppositories.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022172

Enrollment

Registered

2016-05-02

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium, nausea and vomiting

Interventions

Patients use olanzapine suppositories as a treatment for delirium or nausea and vomiting at the time of oral feeding difficulties. Patients are administered 2.5 mg, 5 mg, and 10 mg of olanzapine suppo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We selected to treat for delirium or nausea and vomiting in terminally ill cancer patients with oral feeding difficulties.

Exclusion criteria

Exclusion criteria: We exclude children and patients with taking orally.

Design outcomes

Primary

Measure	Time frame
Responses to olanzapine therapy are evaluated based on clinical assessments by physicians. Information about the side effects is extracted from the electronic medical records of each patient.	—

Countries

Japan

Contacts

Public ContactMasayuki Miyazawa

Shonan Central Hospital Pharmacy

miyazawa@swg.or.jp0466-36-8151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026